PDL BioPharma, Inc.
PDLI
PDLI was delisted on the 30th of December, 2020.
201 hedge funds and large institutions have $397M invested in PDL BioPharma, Inc. in 2016 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 74 increasing their positions, 58 reducing their positions, and 17 closing their positions.
41% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 17
28% more repeat investments, than reductions
Existing positions increased: 74 | Existing positions reduced: 58
3% more funds holding
Funds holding: 196 → 201 (+5)
7% less capital invested
Capital invested by funds: $426M → $397M (-$29.7M)
60% less call options, than puts
Call options by funds: $1.01M | Put options by funds: $2.52M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Mackenzie Financial
Toronto Ontario,
Ontario, Canada
|
+$5.37M |
| 2 |
Norges Bank
Oslo,
Norway
|
+$2.45M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.87M |
| 4 |
CCMH
Cornerstone Capital Management Holdings
New York
|
+$1.59M |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$1.39M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GAM
Gotham Asset Management
New York
|
-$4.8M |
| 2 |
Millennium Management
New York
|
-$3.67M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$3.53M |
| 4 |
AAM
Advisors Asset Management
Monument,
Colorado
|
-$3.36M |
| 5 |
LSV Asset Management
Chicago,
Illinois
|
-$3.03M |
PDLI Hedge Fund Activity: Q2 2016 in Review
201 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in PDL BioPharma, Inc. (PDLI) for Q2 2016, worth a combined $397M — down 7% from $426M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new PDLI positions and 17 closed out — a net gain of 7 holders — while 74 added to existing stakes and 58 trimmed.
The largest buyer was Mackenzie Financial, adding an estimated $5.37M. The largest seller was Gotham Asset Management, cutting an estimated $4.8M.
- 201 institutional investors held PDL BioPharma, Inc. (PDLI) as of Q2 2016, up from 196 in Q1 2016.
- Funds reported $397M of PDL BioPharma, Inc. stock for Q2 2016, down 7% quarter-over-quarter.
- 24 funds opened new PDL BioPharma, Inc. positions in Q2 2016 and 17 closed out, a net change of +7 holders.
- The largest PDL BioPharma, Inc. buyer in Q2 2016 was Mackenzie Financial, an estimated $5.37M added.
- The largest PDL BioPharma, Inc. seller in Q2 2016 was Gotham Asset Management, an estimated $4.8M sold.
Based on aggregated 13F filings for Q2 2016.